



Certificate of Mailing: Date of Deposit: September 4, 2007

I hereby certify under 37 C.F.R. § 1.8(a) that this correspondence is being deposited with the United States Postal Service as first class mail with sufficient postage on the date indicated above and is addressed to Mail Stop RCE, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Sarah Wilcox

Printed name of person mailing correspondence

Signature of person mailing correspondence

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:

Bruno Tocque et al.

Confirmation No.:

2833

Serial No.:

10/070,297

Art Unit:

1634

Filed:

March 5, 2002

Examiner:

Bradley L .Sisson

Customer No.:

21559

Title:

METHODS AND COMPOSITIONS FOR DETECTING

PATHOLOGICAL EVENTS

Mail Stop RCE Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

## INFORMATION DISCLOSURE STATEMENT

Applicants submit the references listed on the enclosed Form PTO-1449, copies of which are enclosed, with the exception of U.S. patents and U.S. patent application publications.

Submission of this statement is not a representation that a search has been made, nor is the inclusion of information in this statement an admission that the information is material to patentability.

Pursuant to 37 C.F.R. § 1.97(b)(4), this statement is being filed before the mailing of a first Office action after the filing of a Request for Continued Examination under 37 C.F.R. § 1.114.

If there are any other charges or any credits, please apply them to Deposit Account No. 03-2095.

Respectfully submitted,

Date: Sytember 4, 2007

ristina Bjeker-Brady, Ph.D

Reg. No/39,109

Clark & Elbing LLP 101 Federal Street Boston, MA 02110

Telephone: 617-428-0200 Facsimile: 617-428-7045

September 4, 2007

Sheet <u>1</u> of <u>4</u> 50146/002002 Attorney Docket No. U.S. DEPARTMENT OF COMMERCE SUBSTITUTE FORM PTO-1449 (MODIFIED) PATENT AND TRADEMARK OFFICE 10/070,297 Serial No. Tocque et al. Applicant INFORMATION DISCLOSURE Filing Date March 5, 2002 STATEMENT BY APPLICANT (Use several sheets if necessary) 1634 Group

IDS Filed

U.S. PATENT DOCUMENTS				
Examiner's Initials	Document Number	Publication Date	Patentee or Applicant	
	5,057,410	10/15/1991	Kawasaki et al.	
	5,445,934	08/29/1995	Fodor et al.	
	5,484,702	01/16/1996	Ludwig	
	5,521,297	05/28/1996	Daggett et al.	
	5,643,729	07/1/1997	Taniguchi et al.	
	5,679,541	10/21/1997	Bonini et al.	
	5,837,832	11/17/1998	Chee et al.	
	5,908,920	06/01/1999	Sidransky	
	6,107,088	08/22/2000	Korneluk et al.	
	6,160,105	12/12/2000	Cunningham et al.	
	6,268,170	07/31/2001	Siddique et al.	
	6,334,316	01/01//2002	Maeda et al.	
	6,849,400	02/01/2005	Harvey et al.	
	6,881,571	04/19/2005	Schweighoffer et al.	<u></u>
	2003/0092033	05/15/2003	Weiner et al.	

FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION				
Examiner's Initials	Document Number	Publication Date	Country or Patent Office	Translation (Yes/No)
	EP 0806478	11/12/1997	Europe	
	FR 2664287	01/10/1992	France	

**EXAMINER** 

(37 C.F.R. § 1.98(b))

DATE CONSIDERED

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.

50146/002002 Attorney Docket No. U.S. DEPARTMENT OF COMMERCE SUBSTITUTE FORM PTO-1449 (MODIFIED) PATENT AND TRADEMARK OFFICE Serial No. 10/070,297 Tocque et al. Applicant INFORMATION DISCLOSURE Filing Date March 5, 2002 STATEMENT BY APPLICANT (Use several sheets if necessary) 1634 Group (37 C.F.R. § 1.98(b)) **IDS Filed** September 4, 2007

FOR	EIGN PATENT OR PUBI	ISHED FOREIGN PATENT APPL	ICATION
WO 94/12631	06/09/1994	РСТ	
WO 95/27052	10/12/1995	PCT	
WO 96/26272	08/29/1996	PCT	
WO 96/30512	10/03/1996	PCT	
WO 97/04092	02/06/1997	PCT	
WO 97/10365	03/20/1997	PCT	
WO 97/13877	04/17/1997	PCT	
WO 97/27317	07/31/1997	PCT	
WO 97/29212	08/14/1997	PCT	
WO 97/46679	12/11/1997	PCT	
WO 98/02576	01/22/1998	PCT	
WO 99/10529	03/04/1999	PCT	
WO 99/42606	08/26/1999	PCT	
WO 00/12760	03/09/2000	PCT	


	OTHER DOCUMENTS (INCLUE	DING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)	
	Alon et al, "Broad Patterns of Gene Tissues Probed by Oligionucleotide	Expression Revealed by Clustering Analysis of Tumor and Normal Colon Arrays," <i>Proc. Natl. Acad. Sci. USA</i> 96:6745-6750 (1999).	
	Ambartsumian et al., "Characterization of Two Splice Variants of Metastasis-Associated Human <i>mts1</i> Gene," <i>Gene</i> 159(1):125-130 (1995).		
	Ardley et al., "Rapid Isolation of Gel Identification and Localisation of UE Family," Cytogenet. Cell Genet. 79:	nomic Clones for Individual Members of Human Multigene Families: BE2L4, A Novel Member of a Ubiquitin Conjugating Enzyme Dispersed Gene 188-192 (1997).	
	Black, "Protein Diversity from Altern Cell 103:367-370 (2000).	native Splicing: A Challenge for Bioinformatics and Post-Genome Biology,"	
EXAMINER		DATE CONSIDERED	



50146/002002 Attorney Docket No. SUBSTITUTE FORM PTO-1449 (MODIFIED) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE 10/070,297 Serial No. Applicant Tocque et al. INFORMATION DISCLOSURE Filing Date March 5, 2002 STATEMENT BY APPLICANT (Use several sheets if necessary) 1634 Group **IDS Filed** September 4, 2007 (37 C.F.R. § 1.98(b))

 OTHER DOCUMENTS (INCLUDING AUTHO	OR, TITLE, DATE, PLACE OF PUBLICATION)
 Bloom et al., "Identification and Tissue-Specific Natl. Acad. Sci. USA 93(24):14188-14192 (1996)	Expression of PDE7 Phosphodiesterase Splice Variants," <i>Proc.</i> 6).
Bonass et al., "The Rat Amelogenin Gene - Som 10:182-186 (1996).	ne Aspects of Evolution and Expression" Adv. Dent. Res.
 Canton et al., "Identification, Molecular Cloning, Receptor Produced by Alternative Splicing," Mol	and Distribution of a Short Variant of the 5-Hydroxytryptamine <sub>2c</sub> <i>J. Pharmacol.</i> 50(4):799-807 (1996).
Cheng et al., "Protection from Fas-Mediated Apo 263(5154):1759-1762 (1994).	optosis by a Soluble Form of the Fas Molecule," Science
Cichon et al, "Pharmacogenetics of Schizophren	nia," Am. J. Med. Genet. 97:98-106 (2000).
Cooper et al., "Gene Therapy Advances: Utilizat Enzyme/Prodrug Therapy (cept) Approach to Pri 19:80-84 (1996).	ion of Alternative Splicing as a Control Element in the Chimeric- imary and Metastatic Tumors," Journal of Clinical Ligand Assay
Drmanac et al., "Gene-Representing cDNA Clus Libraries with Short Oligonucleotide Probes," <i>Ge</i>	sters Defined by Hybridization of 57,419 Clones from Infant Brain enomics 37:29-40 (1996).
 Fong et al., "Epidermal Growth Factor Induces C Expression in A431 Cells," <i>Biochim. Biophys. Ac</i>	Gadd45 (Growth Arrest and DNA Damage Inducible Protein) cta. 1517:250-256 (2001).
lon et al., "A Novel Mutation in the Putative DNA Associated with an Atypical Form of the ATR-X S	Na Helicase <i>XH2</i> is Responsible for Male-to-Female Sex Reversal Syndrome," <i>Am. J. Hum. Genet</i> . 58(6):1185-1191 (1996).
 Komarova et al., "Stress-Induced Secretion of G Oncogene 17:1089-1096 (2003).	rowth Inhibitors: A Novel Tumor Suppressor Function of p53,"
Lisitsyn et al., "Comparative Genomic Analysis of Natl. Acad. Sci. USA 92:151-155 (1995).	of Tumors: Detection of DNA Losses and Amplification," Proc.
Miller et al., "Improved Phenol Emulsion DNA Re Acids Res. 23:2339-2340 (1995).	eassociation Technique (PERT) Using Thermal Cycling," Nucleic
RNAs," J. Virol. 60:1170-1174 (1986).	d to Excise the Small Intron Common to all Minute Virus of Mice
Portion of the Extracellular Domain," Life Sci. 58	nt of the Mouse FAS Antigen with a Deletion in the N-Terminal (9):761-768 (1996).
Prashar et al., "Analysis of Differential Gene Exp Proc. Natl. Acad. Sci. USA 93:659-663 (1996).	pression by Display of 3' End Restriction Fragments of cDNAs,"
Raben, "A Model of mRNA Splicing in Adult Lyst Genet. 5:995-1000 (1996).	osomal Storage Disease (Glycogenosis Type II)," Hum. Mol.
Roemer et al., "p53 Transactivation Domain Mul Mediation of Apoptosis," <i>Oncogene</i> 12:2069-20	tant Q22, S23 is Impaired for Repression of Promoters and 79 (1996).
 AND AND AND AND AND AND AND AND AND AND	DATE CONSIDERED

form with the next communication to applicant.





50146/002002 Attorney Docket No. U.S. DEPARTMENT OF COMMERCE SUBSTITUTE FORM PTO-1449 PATENT AND TRADEMARK OFFICE (MODIFIED) 10/070,297 Serial No. Tocque et al. Applicant INFORMATION DISCLOSURE March 5, 2002 Filing Date STATEMENT BY APPLICANT (Use several sheets if necessary) 1634 Group **IDS Filed** September 4, 2007 (37 C.F.R. § 1.98(b))

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)
Roth et al., "Retrovirus-Mediated Wild-Type p53 Gene Transfer to Tumors of Patients with Lung Cancer," Nat. Med. 2: 985-991 (1996).
Sabbatini et al., "Essential Role for p53-Mediated Transcription in E1A-Induced Apoptosis," Genes Dev. 9: 2184-2192 (1995).
Schena et al., "Parallel Human Genome Analysis: Microarray-Based Expression Monitoring of 1000 Genes," Proc. Natl. Acad. Sci. USA 93:10614-10619 (1996).
Varesco et al., "Mutation in a Splice-Donor Site of the APC Gene in a Family with Polyposis and Late Age of Colonic Cancer Death," <i>Hum. Genet.</i> 93(3): 281-286 (1994).
Virts et al., "Expression of CD45 Isoforms Lacking Exons 7, 8, and 10," Mol. Immunol. 35:167-176 (1998).
Von Stein et al., "A High Throughput Screening for Rarely Transcribed Differentially Expressed Genes," Nuc. Acids Res. 25:2598-2602 (1997).
Wang et al., "Identification of the Genes Responsive to Etoposide-Induced Apoptosis: Application of DNA Chip Technology," FEBS Letters 445:269-273 (1999).
Watanabe et al., "Splicing Isoforms of Rat Ash/Grb2," Biol. Chem. 270(23):13733-13739 (1995).
Wilfinger et al., "PCR-Based Method for Isolation of Full-Length Clones and Splice Variants from cDNA Libraries," BioTechniques 22:481-486 (1997).
Zhao et al., "High-Density cDNA Filter Analysis: A Novel Approach for Large-Scale, Quantitative Analysis of Gene Expression," <i>Gene</i> , 156:207-213 (1995)
Zhu et al., "Deletion within the Src Homology Doman 3 of Bruton's Tyrosine Kinase Resulting in X-linked Agammaglobulinemia (XLA)," <i>J. Exp. Med.</i> 180(2):461-470 (1994).